1. Home
  2. Directory
  3. District Of Columbia
  4. Washington
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1487949335

DR. JULIA MARIE CUNNINGHAM M.D.
Prescription History 1487949335
Internal Medicine - Hematology & Oncology in Washington, DC


Quality Rating: 76.55 out of 100 score

NPI Status: Active since June 17, 2011

Contact Information

3800 RESERVOIR RD NW
DEPARTMENT OF HEMATOLOGY/ONCOLOGY
WASHINGTON, DC
ZIP 20007
Phone: (202) 444-0198
Fax: (202) 444-8829

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JULIA MARIE CUNNINGHAM M.D., an active Hematology & Oncology specialist practicing in Washington, DC. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 182 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 40 claims alone.

Medication Index

C
E
H
I
W
X
No matching medications currently found on file.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 27
30-Day Fills 27.0
Days Supply 810
DC State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.8
Peer Average Days Supply594
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 42.1% more claims than the standard regional baseline profile for DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $363,252.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,453.81

State Avg Cost Per Claim

$14,984.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 40
30-Day Fills 68.0
Days Supply 2,017
DC State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills78.4
Peer Average Days Supply2,198
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $40,280.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,007.01

State Avg Cost Per Claim

$876.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Enoxaparin Sodium

Generic Formulation: Enoxaparin SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 625
DC State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.7
Peer Average Days Supply429
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,280.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$376.40

State Avg Cost Per Claim

$347.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enoxaparin is used to prevent and treat harmful blood clots. This helps to reduce the risk of a stroke or heart attack. This medication helps keep your blood flowing smoothly by lowering the activity of clotting proteins in the blood. Enoxaparin is an anticoagulant, also known as a blood thinner. It is a type of heparin. Conditions which increase your risk of developing blood clots include certain types of surgeries (such as knee/hip replacement, abdominal), long periods of being immobile, certain types of heart attack, and a specific type of chest pain called unstable angina. For some medical conditions, enoxaparin may be used in combination with other blood thinners.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 26
30-Day Fills 51.2
Days Supply 1,536
DC State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills48.7
Peer Average Days Supply1,452
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $659.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.35

State Avg Cost Per Claim

$41.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
DC State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.1
Peer Average Days Supply599
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $203,573.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,964.43

State Avg Cost Per Claim

$15,788.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Warfarin Sodium

Generic Formulation: Warfarin SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 63.9
Days Supply 1,916
DC State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills56.9
Peer Average Days Supply1,668
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,227.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$55.80

State Avg Cost Per Claim

$15.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Therapeutic Applications

This medication is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and/or to prevent new clots from forming in your body. Preventing harmful blood clots helps to reduce the risk of a stroke or heart attack. Conditions that increase your risk of developing blood clots include a certain type of irregular heart rhythm (atrial fibrillation), heart valve replacement, recent heart attack, and certain surgeries (such as hip/knee replacement). Warfarin is commonly called a blood thinner, but the more correct term is anticoagulant. It helps to keep blood flowing smoothly in your body by decreasing the amount of certain substances (clotting proteins) in your blood.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 33
30-Day Fills 63.0
Days Supply 1,890
DC State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills61.1
Peer Average Days Supply1,698
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $34,706.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,051.72

State Avg Cost Per Claim

$924.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JULIA MARIE CUNNINGHAM M.D. provides transparency into local medical care patterns within Washington, DC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.